VCYTMEDIUM SIGNALOPPORTUNITY10-K

VCYT demonstrated strong operational execution with operating income surging 258% and significant improvement in profitability metrics while positioning for growth through MRD platform launch and international expansion.

The company has achieved a meaningful inflection point in profitability with operating income jumping from $16.1M to $57.8M, suggesting successful cost management and scale benefits from revenue growth. Strategic focus has sharpened around TrueMRD launch for minimal residual disease testing and Prosigna's U.S. launch, indicating clear near-term growth catalysts beyond their core oncology franchise.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

VCYT delivered exceptional financial performance with revenue growing 16% to $517.1M while operating leverage drove operating income up 258% and net income up 175%. The company strengthened its balance sheet significantly with cash increasing 52% to $362.6M, current liabilities declining 24%, and operating cash flow jumping 82% to $136.3M. This combination of accelerating profitability, improving cash generation, and stronger liquidity position signals the company has reached sustainable profitability while funding growth investments.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+257.9%
$16.1M→$57.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+174.9%
$24.1M→$66.4M

Net income grew 174.9% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+81.5%
$75.1M→$136.3M

Operating cash flow surged 81.5% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
-66.2%
$677K→$229K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+51.7%
$239.1M→$362.6M

Cash position surged 51.7% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+31.2%
$372.3M→$488.4M

Current assets grew 31.2% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-23.8%
$78.6M→$59.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-22.3%
$124.1M→$96.4M

Liabilities reduced 22.3% — deleveraging improves balance sheet strength and financial flexibility.

Gross Profit
P&L
+21.6%
$298.1M→$362.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+16%
$445.8M→$517.1M

Revenue growing 16% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
"Veracyte," "Afirma," "Percepta," "Envisia," "Prosigna," "Lymphmark," "Decipher," "GRID," "C2i", "C2i Genomics" and the Veracyte logo are registered trademarks, and "TrueMRD" is a pending trademark application, of Veracyte, Inc.
Our international distribution of IVDs is currently focused on our Prosigna test and, in the future, we intend to offer Decipher Prostate as an IVD.
In the near-term, we are focused on continuing to expand Decipher Prostate's penetration and leadership position while also sustaining strong growth for Afirma.
In particular, we are prioritizing the following growth drivers: the launch of TrueMRD, our minimal residual disease, or MRD, platform to expand our reach further across the cancer care continuum and the launch of Prosigna as an LDT for the U.S.
market to be able to serve more patients in the United States who face a breast cancer diagnosis.
+7 more — sign up free →
REMOVED
When used in this report, all references to "Veracyte," the "company," "we," "our" and "us" refer to Veracyte, Inc., together with its consolidated subsidiaries, unless otherwise noted.
Immunoscore is the registered trademark of Institut National de la Sant et de la Recherche M dicale, or Inserm, in the United States and selected countries and used by Veracyte under license.
Additionally, our Percepta Nasal Swab test is currently being run in our CLIA labs in support of clinical studies.
Our international distribution of IVDs is currently limited to our Prosigna test, however, in the future, we intend to offer Decipher Prostate and Percepta Nasal Swab as IVDs.
In the near-term, we are focused on continuing to expand Decipher Prostate's market size, penetration, and leadership position while also sustaining strong growth for Afirma.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →